IgG4-related pleural disease in a patient with pulmonary adenocarcinoma under durvalumab treatment: a case report

BACKGROUND: Immune checkpoint inhibitors (ICIs) are the standard treatment for non-small cell lung cancer. The unique adverse events that can arise after treatment with ICIs are known as immune-related adverse events (irAE). As the number of cases under treatment with ICIs increases, new types of ch...

Descripción completa

Detalles Bibliográficos
Autores principales: Terashima, Takeshi, Iwami, Eri, Shimada, Takashi, Kuroda, Aoi, Matsuzaki, Tatsu, Nakajima, Takahiro, Sasaki, Aya, Eguchi, Keisuke
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183131/
https://www.ncbi.nlm.nih.gov/pubmed/32334571
http://dx.doi.org/10.1186/s12890-020-1150-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7183131/
https://www.ncbi.nlm.nih.gov/pubmed/32334571
http://dx.doi.org/10.1186/s12890-020-1150-x

Ejemplares similares